GHK-Cu published research history: - First isolated and characterized: 1973 - Continuous peer-reviewed publication: 50+ years - Published research covering: wound healing, skin biology, COPD, oxidative stress, bone, skeletal muscle, gastrointestinal, neurological, gene expression, aging - Mechanistic characterization: Multiple pathways identified, SIRT1 direct binding confirmed in 2025 - Cell and animal model validation: Extensive across multiple tissue types and species Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) research: - Commercial introduction: Early 2000s - Research base: Primarily cosmetic science and dermatology literature - Mechanistic characterization: Primarily focused on TGF-beta receptor and IL-6 pathways - Depth: Narrower tissue focus, smaller body of published mechanistic research For researchers who need a compound with extensive published mechanistic context, detailed gene expression data, or research across multiple tissue types, GHK-Cu's research depth is substantially greater
This review breaks down how the membership model is structured, what recurring billing covers, and one metabolic input the subscription never measures
HttlMMarkovaIMiklankovaDZapletalovaIPorubaMHaluzikMet al
Effect of acetyl-L-carnitine on the dopaminergic system in aging brain J Neurosci Res 1991
Components of this system include carnitine palmitoyltransferase 1 (CPT1) and 2 (CPT2), the carnitineacylcarnitine carrier (CAC), and the carnitine acetyltransferase (CrAT, also known as CAT)
